Dr Alexander Cohen speaks to ecancer at the ASH 2019 meeting in Orlando about the data he was presenting on the safety and effectiveness of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer.
He says the observational study found that there was a lower rate of major bleeding and reduced recurrences of venous thromboembolism in patients who were treated with apixaban.
Dr Cohen comments that this is good news for patients who tend to prefer oral therapies to injectable therapies. There are also greater adherence and persistence rates with oral therapies, which results in better outcomes.
With regards to next steps, Dr Cohen explains that the optimal length of anticoagulant therapy is still unknown.